BioAlliance Pharma: Q3 2009: Strong Sales Growth and Significant Progress in Clinical Development

October 21, 2009 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

PARIS--(BUSINESS WIRE)--Regulatory News: BioAlliance Pharma SA (Paris:BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced a consolidated turnover of €1.6 million for the third quarter of 2009.

Twitter
LinkedIn
Facebook
Email
Print

Earnings Europe